Small Molecular Drug, AMS-2140

AMS derives its name from 'Anti-Microbial Savior,' reflecting our steadfast commitment towards pioneering new antibiotics to combat a spectrum of superbugs. Moreover, our primary focus lies in anti-viral drug research, with particular emphasis on developing small molecule drug candidates tailored for RNA viruses. Until this year, our focus has been directed towards addressing various challenging diseases, such as Covid 19, Dengue Virus (DENV), Zika Virus, Avian Flu, and more. Leveraging our proprietary extraction technology, ExtrO, we have successfully isolated potential compounds: Yuan-01, Yuan-03, both are from medicinal fungi. "Recently, we've successfully isolated a potent antiviral compound, AMS-2140, derived from Pongamia tree" Based on verified research, AMS-2140 shows broad spectrum anit-virus activity with non-toxicity, we anticipate that it possesses substantial potential for the treatment of dengue fever in the nearfuture. Overall, our ultimate objective is to discover efficacious treatments tailored to combat these formidable diseases. In the post-pandemic era, the development of vaccines and pharmaceuticals is paramount. Beyond COVID-19, potential global health threats loom from viruses like Avian Influenza, Norovirus, Enterovirus, and Respiratory Syncytial Virus (RSV). AMS BioteQ, committed to pioneering cutting-edge technologies, prioritizes crafting innovative antibiotics to combat a spectrum of superbugs and emerging viruses in the post-pandemic landscape. Rooted in Taiwan with global perspective, we aspire to lead and redefine the pharmaceutical market and shaping the future of healthcare worldwide.